Davide Molho Sells 11,717 Shares of Charles River Laboratories Intl. Inc (CRL) Stock

Charles River Laboratories Intl. Inc (NYSE:CRL) insider Davide Molho sold 11,717 shares of Charles River Laboratories Intl. stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $90.00, for a total value of $1,054,530.00. Following the transaction, the insider now directly owns 28,266 shares of the company’s stock, valued at $2,543,940. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Charles River Laboratories Intl. Inc (NYSE:CRL) opened at 89.19 on Tuesday. Charles River Laboratories Intl. Inc has a 12-month low of $67.20 and a 12-month high of $91.57. The stock has a 50 day moving average price of $86.28 and a 200-day moving average price of $80.06. The firm has a market capitalization of $4.23 billion, a PE ratio of 27.65 and a beta of 0.99.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Tuesday, February 14th. The company reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.10. Charles River Laboratories Intl. had a return on equity of 25.75% and a net margin of 9.05%. The business earned $466.80 million during the quarter, compared to analyst estimates of $441.64 million. During the same period in the prior year, the company posted $1.00 EPS. The business’s revenue for the quarter was up 31.9% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories Intl. Inc will post $5.06 EPS for the current year.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Your IP Address:

Institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio raised its position in shares of Charles River Laboratories Intl. by 159.9% in the second quarter. Public Employees Retirement System of Ohio now owns 31,415 shares of the company’s stock worth $2,590,000 after buying an additional 19,329 shares during the period. Royal Bank of Canada raised its position in shares of Charles River Laboratories Intl. by 2.0% in the second quarter. Royal Bank of Canada now owns 419,248 shares of the company’s stock worth $34,563,000 after buying an additional 8,236 shares during the period. Northwestern Mutual Investment Management Company LLC raised its position in shares of Charles River Laboratories Intl. by 1.0% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 8,144 shares of the company’s stock worth $671,000 after buying an additional 84 shares during the period. Eqis Capital Management Inc. raised its position in shares of Charles River Laboratories Intl. by 2.9% in the third quarter. Eqis Capital Management Inc. now owns 3,485 shares of the company’s stock worth $290,000 after buying an additional 98 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of Charles River Laboratories Intl. by 559.2% in the third quarter. BNP Paribas Arbitrage SA now owns 170,577 shares of the company’s stock worth $14,216,000 after buying an additional 144,702 shares during the period. 95.32% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating on shares of Charles River Laboratories Intl. in a report on Thursday, March 16th. Evercore ISI raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $86.50 price objective for the company in a report on Wednesday, January 4th. Goldman Sachs Group Inc raised Charles River Laboratories Intl. from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $75.00 to $77.00 in a report on Friday, December 16th. They noted that the move was a valuation call. Finally, Barclays PLC raised Charles River Laboratories Intl. from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $65.00 to $77.00 in a report on Wednesday, November 30th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $85.95.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024561/davide-molho-sells-11717-shares-of-charles-river-laboratories-intl-inc-crl-stock.html

Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.